|
Written by John Hoeffel, LA Times
|
|
Thursday, 18 February 2010 18:59 |
As an $8.7-million state research effort comes to an end, investigators report that cannabis can significantly relieve neuropathic pain and reduce muscle spasms in MS patients. More research is urged.With an innovative but little-known state program to study medical marijuana about to run out of money, researchers and political supporters said Wednesday the results show promise.
"It should take all the mystery out of whether it works. We've got the results," said former state Sen. John Vasconcellos, who led the effort to create the 10-year-old Center for Medicinal Cannabis Research.
|
|
Last Updated on Thursday, 18 February 2010 19:03 |
|
|
Written by Tim C
|
|
Tuesday, 28 April 2009 05:58 |
|
|
|
Written by Tim C
|
|
Wednesday, 08 April 2009 01:48 |
Conflict of interest by University of Mississippi professor exposed
Washington, D.C. -- Medical marijuana advocates issued a report today aimed at drawing attention to the federal government's monopoly on the production of marijuana for medical research. The 14-page report, entitled "Obstruction of Medical Cannabis Research in the U.S.," highlights the federal effort to impede therapeutic research on marijuana and exposes a conflict of interest for University of Mississippi professor Mahmoud ElSohly, who holds an exclusive cultivation license issued by the Drug Enforcement Administration (DEA). |
|
Written by Tim C
|
|
Monday, 30 March 2009 01:59 |
|
ADDISON, Texas--(BUSINESS WIRE)--Gulf Onshore Inc (OTCBB: GFON.OB - News) announced today that it has acquired the assets of Cannex Therapeutics and will continue development of its medical cannabis-based pharmaceutical products. Cannex Therapeutics is a privately owned California group founded and operated by Medical Cannabis pioneer and entrepreneur Steven W. Kubby (www.kubby.com). The asset purchase agreement includes all intellectual property rights, formulas, patents, trademarks, client base, hardware and software pertaining to Cannex's pharmaceutical cannabis research & development business. |
|
Written by Fred Gardner
|
|
Friday, 13 March 2009 08:13 |
Two plants strains relatively rich in cannabidiol (CBD) have been identified by an analytic test lab recently established to serve the medical cannabis industry in California. That's two major stories in one sentence. Let's take it from the bottom…
In December a lab in the East Bay started testing samples of cannabis for pathogenic mold and the presence of three cannabinoids –THC, CBD and CBN (cannabinol). THC is the main psychoactive compound in the cannabis plant. CBD is a cannabinoid with intriguing medical potential that gets bred out of cannabis when the breeder's goal is high THC content (as it has been in California for generations). CBN is a breakdown product of THC, an indicator of time in storage.
The lab has been testing about 10 samples a day provided by Oakland's Harborside Health Center, whose proprietor, Steve DeAngelo, helped plan and underwrite the venture. Results from the lab are posted on labels affixed to the strains in Harborside's display cases. Thus prospective buyers are informed that the sparkly nuggets of Raspberry Kush they are savoring in a Petri dish are free of dangerous aspergillus and contain 14.3% THC by weight. (Percent CBD and CBN almost always round off to zero. That's about to change.)
Full article by Fred Gardner on Counterpunch: http://counterpunch.org/gardner03132009.html
|
|
Last Updated on Friday, 13 March 2009 08:16 |
|
|
|
|
<< Start < Prev 1 2 Next > End >>
|
|
Page 1 of 2 |
